Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Plos One|August 15, 2015
GNL3L Is a Nucleo-Cytoplasmic Shuttling Protein: Role in Cell Cycle RegulationIndu Jose Thoompumkal, Malireddi Rama Krishna Subba Rao, Anbarasu Kumaraswamy, et al.The Journal of Biological Chemistry|August 25, 2018
The non-enzymatic RAS effector RASSF7 inhibits oncogenic c-Myc functionAnbarasu Kumaraswamy, Anitha Mamidi, Pavitra Desai, et al.European Urology|March 31, 2021
Recent Advances in Epigenetic Biomarkers and Epigenetic Targeting in Prostate CancerAnbarasu Kumaraswamy, Katherine R Welker Leng, Thomas C Westbrook, et al.Neoplasia (New York, N.Y.)|March 15, 2025
LSD1+8a is an RNA biomarker of neuroendocrine prostate cancerAnbarasu Kumaraswamy, Rahul Mannan, Olivia A Swaim, et al.Neoplasia (New York, N.Y.)|May 14, 2020
Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4Daniel J Coleman, David A Sampson, Archana Sehrawat, et al.Cancer Research|February 23, 2022
Understanding Drug Sensitivity and Tackling Resistance in CancerJeffrey W Tyner, Franziska Haderk, Anbarasu Kumaraswamy, et al.Biorxiv : the Preprint Server for Biology|July 30, 2026
Genomic Determinants of Lethality and Therapeutic Vulnerability in Castration-Resistant Prostate CancerRyan J Rebernick, Liat Hammer, Mahnoor Gondal, et al.JCI Insight|July 13, 2023
LSD1 promotes prostate cancer reprogramming by repressing TP53 signaling independently of its demethylase functionAnbarasu Kumaraswamy, Zhi Duan, Diana Flores, et al.NPJ Precision Oncology|July 7, 2025
Transcriptional profiling clarifies a program of enzalutamide extreme non-response in lethal prostate cancerAnbarasu Kumaraswamy, Ya-Mei Hu, Joel A Yates, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2021
BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity ProgramDae-Hwan Kim, Duanchen Sun, William K Storck, et al.Pageof 2